- call +1-201-465-4211
- email sales@mrinsights.biz
Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2.
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
According to this study, over the next five years the Isocitrate Dehydrogenase Inhibitors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Isocitrate Dehydrogenase Inhibitors business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Isocitrate Dehydrogenase Inhibitors market by product type, application, key manufacturers and key regions and countries.
This study considers the Isocitrate Dehydrogenase Inhibitors value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
DH Inhibitor
FLT3 Inhibitor
Hedgehog Pathway Inhibitor
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Isocitrate Dehydrogenase Inhibitors consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Isocitrate Dehydrogenase Inhibitors market by identifying its various subsegments.
Focuses on the key global Isocitrate Dehydrogenase Inhibitors manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Isocitrate Dehydrogenase Inhibitors with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Isocitrate Dehydrogenase Inhibitors submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
2019-2024 Global Isocitrate Dehydrogenase Inhibitors Consumption Market Report
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Isocitrate Dehydrogenase Inhibitors Consumption 2014-2024
2.1.2 Isocitrate Dehydrogenase Inhibitors Consumption CAGR by Region
2.2 Isocitrate Dehydrogenase Inhibitors Segment by Type
2.2.1 IDH1 Mutant Medullary Malignant Tumor
2.2.2 IDH2 Mutant Medullary Malignant Tumor
2.2.3 Others
2.3 Isocitrate Dehydrogenase Inhibitors Consumption by Type
2.3.1 Global Isocitrate Dehydrogenase Inhibitors Consumption Market Share by Type (2014-2019)
2.3.2 Global Isocitrate Dehydrogenase Inhibitors Revenue and Market Share by Type (2014-2019)
2.3.3 Global Isocitrate Dehydrogenase Inhibitors Sale Price by Type (2014-2019)
2.4 Isocitrate Dehydrogenase Inhibitors Segment by Application
2.4.1 DH Inhibitor
2.4.2 FLT3 Inhibitor
2.4.3 Hedgehog Pathway Inhibitor
2.4.4 Others
2.5 Isocitrate Dehydrogenase Inhibitors Consumption by Application
2.5.1 Global Isocitrate Dehydrogenase Inhibitors Consumption Market Share by Application (2014-2019)
2.5.2 Global Isocitrate Dehydrogenase Inhibitors Value and Market Share by Application (2014-2019)
2.5.3 Global Isocitrate Dehydrogenase Inhibitors Sale Price by Application (2014-2019)
3 Global Isocitrate Dehydrogenase Inhibitors by Manufacturers
3.1 Global Isocitrate Dehydrogenase Inhibitors Sales Market Share by Manufacturers
3.1.1 Global Isocitrate Dehydrogenase Inhibitors Sales by Manufacturers (2017-2019)
3.1.2 Global Isocitrate Dehydrogenase Inhibitors Sales Market Share by Manufacturers (2017-2019)
3.2 Global Isocitrate Dehydrogenase Inhibitors Revenue Market Share by Manufacturers
3.2.1 Global Isocitrate Dehydrogenase Inhibitors Revenue by Manufacturers (2017-2019)
3.2.2 Global Isocitrate Dehydrogenase Inhibitors Revenue Market Share by Manufacturers (2017-2019)
3.3 Global Isocitrate Dehydrogenase Inhibitors Sale Price by Manufacturers
3.4 Global Isocitrate Dehydrogenase Inhibitors Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
3.4.1 Global Isocitrate Dehydrogenase Inhibitors Manufacturing Base Distribution and Sales Area by Manufacturers
3.4.2 Players Isocitrate Dehydrogenase Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Isocitrate Dehydrogenase Inhibitors by Regions
4.1 Isocitrate Dehydrogenase Inhibitors by Regions
4.1.1 Global Isocitrate Dehydrogenase Inhibitors Consumption by Regions
4.1.2 Global Isocitrate Dehydrogenase Inhibitors Value by Regions
4.2 Americas Isocitrate Dehydrogenase Inhibitors Consumption Growth
4.3 APAC Isocitrate Dehydrogenase Inhibitors Consumption Growth
4.4 Europe Isocitrate Dehydrogenase Inhibitors Consumption Growth
4.5 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption Growth
5 Americas
5.1 Americas Isocitrate Dehydrogenase Inhibitors Consumption by Countries
5.1.1 Americas Isocitrate Dehydrogenase Inhibitors Consumption by Countries (2014-2019)
5.1.2 Americas Isocitrate Dehydrogenase Inhibitors Value by Countries (2014-2019)
5.2 Americas Isocitrate Dehydrogenase Inhibitors Consumption by Type
5.3 Americas Isocitrate Dehydrogenase Inhibitors Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Isocitrate Dehydrogenase Inhibitors Consumption by Countries
6.1.1 APAC Isocitrate Dehydrogenase Inhibitors Consumption by Countries (2014-2019)
6.1.2 APAC Isocitrate Dehydrogenase Inhibitors Value by Countries (2014-2019)
6.2 APAC Isocitrate Dehydrogenase Inhibitors Consumption by Type
6.3 APAC Isocitrate Dehydrogenase Inhibitors Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 Europe
7.1 Europe Isocitrate Dehydrogenase Inhibitors by Countries
7.1.1 Europe Isocitrate Dehydrogenase Inhibitors Consumption by Countries (2014-2019)
7.1.2 Europe Isocitrate Dehydrogenase Inhibitors Value by Countries (2014-2019)
7.2 Europe Isocitrate Dehydrogenase Inhibitors Consumption by Type
7.3 Europe Isocitrate Dehydrogenase Inhibitors Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Isocitrate Dehydrogenase Inhibitors by Countries
8.1.1 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption by Countries (2014-2019)
8.1.2 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Value by Countries (2014-2019)
8.2 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption by Type
8.3 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Isocitrate Dehydrogenase Inhibitors Distributors
10.3 Isocitrate Dehydrogenase Inhibitors Customer
11 Global Isocitrate Dehydrogenase Inhibitors Market Forecast
11.1 Global Isocitrate Dehydrogenase Inhibitors Consumption Forecast (2019-2024)
11.2 Global Isocitrate Dehydrogenase Inhibitors Forecast by Regions
11.2.1 Global Isocitrate Dehydrogenase Inhibitors Forecast by Regions (2019-2024)
11.2.2 Global Isocitrate Dehydrogenase Inhibitors Value Forecast by Regions (2019-2024)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Isocitrate Dehydrogenase Inhibitors Forecast by Type
11.8 Global Isocitrate Dehydrogenase Inhibitors Forecast by Application
12 Key Players Analysis
12.1 AGIOS
12.1.1 Company Details
12.1.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.1.3 AGIOS Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.1.4 Main Business Overview
12.1.5 AGIOS News
12.2 Aslan Pharmaceuticals
12.2.1 Company Details
12.2.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.2.3 Aslan Pharmaceuticals Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.2.4 Main Business Overview
12.2.5 Aslan Pharmaceuticals News
12.3 Bayer
12.3.1 Company Details
12.3.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.3.3 Bayer Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.3.4 Main Business Overview
12.3.5 Bayer News
12.4 Beigene
12.4.1 Company Details
12.4.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.4.3 Beigene Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.4.4 Main Business Overview
12.4.5 Beigene News
12.5 Bristol-Myers Squibb
12.5.1 Company Details
12.5.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.5.3 Bristol-Myers Squibb Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.5.4 Main Business Overview
12.5.5 Bristol-Myers Squibb News
12.6 Celgene
12.6.1 Company Details
12.6.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.6.3 Celgene Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.6.4 Main Business Overview
12.6.5 Celgene News
12.7 Daiichi Sankyo
12.7.1 Company Details
12.7.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.7.3 Daiichi Sankyo Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.7.4 Main Business Overview
12.7.5 Daiichi Sankyo News
12.8 Philogen S.p.A.
12.8.1 Company Details
12.8.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.8.3 Philogen S.p.A. Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.8.4 Main Business Overview
12.8.5 Philogen S.p.A. News
12.9 Tesaro
12.9.1 Company Details
12.9.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.9.3 Tesaro Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.9.4 Main Business Overview
12.9.5 Tesaro News
12.10 Tragara/Adastra
12.10.1 Company Details
12.10.2 Isocitrate Dehydrogenase Inhibitors Product Offered
12.10.3 Tragara/Adastra Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
12.10.4 Main Business Overview
12.10.5 Tragara/Adastra News
12.11 Tocagen
13 Research Findings and Conclusion
List of Tables and Figures
Figure Picture of Isocitrate Dehydrogenase Inhibitors
Table Product Specifications of Isocitrate Dehydrogenase Inhibitors
Figure Isocitrate Dehydrogenase Inhibi
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
